# ASCENT-07 (NCT05840211)

> Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05840211
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gilead Sciences
- Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer
- Interventions: Sacituzumab Govitecan-hziy; Paclitaxel; Nab-paclitaxel; Capecitabine
- Enrollment: 654
- Primary outcome: Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

## Commentary we found

- X threads: 33
- YouTube: 26
- Podcasts: 14
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ascent-07-nct05840211

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05840211", "email": "<work email>"}; the inbox owner confirms by the emailed link.